Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
A phase 3 trial of Durvalumab, Cisplatin and Capecitabine in oesophageal cancer, run by AstraZeneca, active and no longer recruiting.
Overview
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC is a phase 3 interventional study registered as NCT04550260 by AstraZeneca, with 640 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2027-06-30. Interventions recorded: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine and Radiation.
Similar pages
not linked directly; found by shared links- TrialA Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialDurvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.
Shares Durvalumab, AstraZeneca and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialPhase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Shares Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialA Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
Shares Durvalumab, Cisplatin, AstraZeneca and the tag pipeline.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Capecitabine, Cisplatin, AstraZeneca and the tag pipeline.